Document is current
Any future updates will be listed below
-
Authors
Haar, Markus
Müller, Jakob
Hartwig, Daniela
von Bargen, Julia
Daniels, Rikus
Theile, Pauline
Kluge, Stefan
Roedl, Kevin
-
Funding
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 18 July 2024
Accepted: 2 September 2024
First Online: 11 September 2024
Declarations
:
: Not applicable.
: MH, JM, DH, JvB, RD, PT and KR do not report any conflicts of interest. SK received lecture honoraria from CSl Behring, Merz, Alexion, Advitos, and consultant honorarium from AstraZeneca. SK received research support by Ambu, E.T.View Ltd, Fisher & Paykel, Pfizer and Xenios, lecture honoraria from ArjoHuntleigh, Astellas, Astra, Basilea, Bard, Baxter, Biotest, CSL Behring, CytoSorbents, Fresenius, Gilead, MSD, Orion, Pfizer, Philips, Sedana, Sorin, Xenios and Zoll, and consultant honorarium from AMOMED, Astellas, Baxter, Bayer, Fresenius, Gilead, MSD, Pfizer and Xenios.
: This study protocol was reviewed and approved by the Ethics Committee of the Hamburg Chamber of Physicians in Hamburg, Germany (“Ethikkomission der Ärztekammer Hamburg”), approval number number No.: 2022-300219-WF. Due to the retrospective nature of the study and anonymized data collection the need for informed consent was waived by the Ethics Committee of the Hamburg Chamber of Physicians.
